SEC Form 4 · accession 0000919574-18-003438
KIORA PHARMACEUTICALS INC · KPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
ARMISTICE CAPITAL, LLC
10% Owner
Armistice Capital Master Fund Ltd.
10% Owner
Steven Boyd
10% Owner
Period of report
May 9, 2018
Accepted (ET)
May 11, 2018 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001372514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF3,F1 | May 9, 2018 | P | 103,953 | $0.4961 | A | 16,653,683 | D | |
| Common StockF2 | May 9, 2018 | P$0 | 0 | $0.00 | A | 16,653,683 | I | See Footnote |
| Common StockF2 | May 9, 2018 | P$0 | 0 | $0.00 | A | 16,653,683 | I | See Footnote |
| Common StockF4,F1 | May 10, 2018 | P | 23,917 | $0.5428 | A | 16,677,600 | D | |
| Common StockF2 | May 10, 2018 | P$0 | 0 | $0.00 | A | 16,677,600 | I | See Footnote |
| Common StockF2 | May 10, 2018 | P$0 | 0 | $0.00 | A | 16,677,600 | I | See Footnote |
| Common StockF5,F1 | May 11, 2018 | P | 49,142 | $0.538 | A | 16,726,742 | D | |
| Common StockF2 | May 11, 2018 | P$0 | 0 | $0.00 | A | 16,726,742 | I | See Footnote |
| Common StockF2 | May 11, 2018 | P$0 | 0 | $0.00 | A | 16,726,742 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported securities are directly owned by Armistice Capital Master Fund Ltd.
- F2The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund Ltd. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- F3This constitutes the weighted average purchase price. The prices range from $0.4870 to $0.5014. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F4This constitutes the weighted average purchase price. The prices range from $0.5259 to $0.5535. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F5This constitutes the weighted average purchase price. The prices range from $0.5302 to $0.5559. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.